Case Details
- Citation: [2016] SGHC 106
- Title: Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd
- Court: High Court of the Republic of Singapore
- Date: 26 May 2016
- Judges: George Wei J
- Case Number: Suit No 390 of 2015 (Summons No 4136 of 2015)
- Decision Type: Application for leave to amend patent (dismissed)
- Plaintiff/Applicant: Warner-Lambert Company LLC
- Defendant/Respondent: Novartis (Singapore) Pte Ltd
- Counsel for Plaintiff: Stanley Lai Tze Chang, SC; Gloria Goh En-Ci and Clara Tung Yi Lin (Allen & Gledhill LLP)
- Counsel for Defendant: Suhaimi Bin Lazim and Chow Jian Hong (Mirandah Law LLP)
- Legal Areas: Patents and Inventions — Industrial application; Patents and Inventions — Novelty
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed); Medicines Act (Cap 176, 1985 Rev Ed); UK Patents Act 1977; (also referenced) CIPA Guide to the Patents Act
- Key Provisions Mentioned: s 83(1) and s 84(3) of the Patents Act; s 25(5) of the Patents Act; s 36 of the Patents Act; s 12A(3)(a) of the Medicines Act; O 87A r 11(1) of the Rules of Court
- Related Appellate History: Appeal to this decision in Civil Appeal No 121 of 2016 dismissed by the Court of Appeal on 1 August 2017 (see [2017] SGCA 45)
- Judgment Length: 29 pages, 16,981 words
Summary
Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd concerned an application by the patent proprietor for leave to amend its Singapore patent in the context of ongoing infringement proceedings and a pending counterclaim for revocation. The patent related to pregabalin (marketed as Lyrica) and, as granted, claimed a monopoly over the use of pregabalin for treating pain. With the patent nearing the end of its 20-year term, the proprietor sought to amend the claims to a “Swiss-style” format—namely, “use of compound X in the manufacture of a medicament for a specified (and new) therapeutic use Y”.
The High Court (George Wei J) dismissed the application for leave to amend. While the court accepted that it was generally inappropriate to decide validity issues in the same procedural step as an amendment application, it nonetheless held that the proposed amendments faced serious legal obstacles. In particular, the amendments were found to be impermissible under the statutory constraints on amendments (including the prohibition on adding “additional matter” and on extending the protection conferred by the patent). The court also exercised its discretion against the proprietor, citing factors such as unreasonable delay and the pursuit of an advantage from a patent that was alleged to have always been invalid.
What Were the Facts of This Case?
The plaintiff, Warner-Lambert, owned a pharmaceutical patent in Singapore that claimed pregabalin for the treatment of pain. The active ingredient pregabalin is used in medicines for neuropathic pain and other chronic pain disorders, including fibromyalgia. The plaintiff manufactured and distributed Lyrica, which contains pregabalin and is approved by Singapore’s Health Sciences Authority (HSA) for relevant indications.
The patent was filed on 16 July 1997 and granted in Singapore on 23 May 2000. Under the Patents Act, patent protection in Singapore runs for 20 years from the filing date. By 2015, the patent was approaching the end of its term, which became relevant to the procedural posture and the court’s assessment of delay and the fairness of granting amendments at that stage.
On 23 March 2015, the plaintiff received notice that the defendant, Novartis, had applied to the HSA for product licences for pregabalin products. The notice was made pursuant to s 12A(3)(a) of the Medicines Act. In the notice, Novartis alleged that the defendant’s intended acts for which the product licences were sought would not infringe the plaintiff’s patent.
In response, on 21 April 2015, the plaintiff commenced an action seeking, among other relief, a declaration that the defendant’s acts would infringe the patent. Shortly thereafter, on 5 May 2015, the plaintiff notified the defendant of its intention to apply to amend the patent. The proposed amendments were advertised on 29 June 2015 in accordance with O 87A r 11(1) of the Rules of Court, and the defendant filed a notice of opposition on 24 July 2015. On 26 August 2015, the plaintiff brought the present application to amend the patent claims.
What Were the Key Legal Issues?
The central issue was whether the plaintiff should be granted leave to amend its patent under s 83(1) of the Patents Act. This required the court to consider the statutory framework governing amendments, including the limits imposed by s 84(3) (which prevents amendments that disclose additional matter or extend the protection conferred by the patent) and the “base-line criteria” for claim clarity and conciseness under s 25(5).
A second, logically anterior issue concerned the scope of the court’s review at the amendment stage. The defendant argued that the proposed amendments would be futile because the amended patent would still fail the requirements of patentability—novelty, inventive step, and industrial application. The court had to decide whether it should assess validity as part of the amendment application, or whether validity should be left for the trial of the main action where expert evidence could be properly tested.
Finally, the court had to decide whether, even if the amendments were not clearly invalid, it should exercise its discretion to refuse leave. The defendant relied on discretionary factors including unreasonable delay, the alleged unfairness of seeking advantage from a patent that was said to have always been invalid, and the adequacy of disclosure by the plaintiff regarding relevant matters connected to the proposed amendments.
How Did the Court Analyse the Issues?
George Wei J began by clarifying the procedural and statutory basis for the application. The court emphasised that the application was governed by s 83 of the Patents Act because there were pending court proceedings in which validity had been put in issue. The Registrar’s general power to allow amendments under s 38 was therefore inapplicable. The court also noted that the UK Patents Act 1977 contains analogous provisions, and it referred to the CIPA Guide to explain the policy rationale: where validity is already in issue (or could have been put in issue), amendment applications should be handled under the court’s constrained statutory framework.
On the substantive law of amendments, the court reiterated that the power to amend is circumscribed. Section 84(3) prevents amendments that (i) result in the specification disclosing additional matter, and (ii) extend the protection conferred by the patent. The court also referred to the “base-line criteria” in s 25(5), which require claims to be clear and concise. In addition, while the court has a general discretion, the exercise of that discretion is guided by established factors, including those articulated in Smith Kline & French Laboratories v Evans Medical Limited. The court’s approach therefore combined statutory limits with discretionary fairness.
Turning to the “futility” argument, the court identified a logically anterior question: whether validity should be considered alongside the pre-requisites for amendment. The court relied on Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781 (“Ship’s Equipment”), where Lee Seiu Kin J had rejected the approach of deciding validity at the amendment stage when validity was scheduled to be heard later. The High Court agreed that it was inappropriate to hear validity issues together with the amendment application. The court reasoned that, even if it is sometimes possible to refuse an amendment where it is clearly pointless or where the amended patent would still be clearly invalid, that was not the position on the material before it.
In this case, the court found that it was “far from clear” whether the amended patent would be invalid. The parties intended to adduce expert evidence on validity. Accordingly, the court held that it would be more expedient to leave validity to the trial of the main action, where the issues could be more adequately ventilated and tested. This approach also avoided prejudice to the defendant, because the defendant would have ample opportunity to challenge validity after the amendment application was disposed of.
However, the court did not stop at the procedural point. It then addressed the defendant’s other grounds of opposition, particularly those tied to the statutory constraints on amendments. The proposed amendments were, in essence, a change in claim format: from a claim to a method of treatment to a “Swiss-style” claim. The generalised form was “use of compound X in the manufacture of a medicament for a specified (and new) therapeutic use Y”. This change was designed to respond to the defendant’s counterclaim that the granted patent claimed a monopoly over methods of treatment of the human or animal body, which are not patentable in Singapore.
Although the court accepted that the amendment sought to address a patentability objection, it held that the proposed amendments ran into the prohibitions in s 84(3). The court found that the amendments would result in impermissible additional matter and/or extend the protection conferred by the patent. The practical effect of such a finding is significant: even if the amendment could theoretically improve the patent’s chances of surviving a novelty or patentability challenge, the court cannot permit amendments that cross the statutory line. The court’s analysis therefore treated s 84(3) as a hard constraint, not merely a factor in discretion.
Finally, the court considered whether to exercise its discretion against the plaintiff. It accepted that discretionary factors could justify refusal even if the amendment were not clearly invalid. The court identified three key discretionary concerns raised by the defendant: (i) unreasonable delay in seeking the amendments; (ii) the plaintiff’s attempt to obtain an unfair advantage from a patent it knew (or should have known) was and always had been invalid; and (iii) failure to make full disclosure of all relevant matters relating to the proposed amendments. The court’s reasoning reflects a broader principle in patent amendment jurisprudence: amendment should not be used as a tactical device to salvage a weak or defective patent at a late stage, particularly where the proprietor’s conduct and timing raise fairness concerns.
What Was the Outcome?
The High Court dismissed Warner-Lambert’s application for leave to amend its patent. The dismissal meant that the patent remained in its granted form for the purposes of the ongoing infringement proceedings, subject to the defendant’s counterclaim for revocation and the trial of validity issues in due course.
In practical terms, the decision prevented the proprietor from re-framing its claims into a Swiss-style format that might have better aligned with patentability requirements for pharmaceutical use claims. The court’s refusal also underscores that amendment applications are not a “second bite at the cherry” where statutory limits and discretionary fairness considerations are not met.
Why Does This Case Matter?
This case is important for practitioners because it clarifies how Singapore courts approach patent amendments when validity is already in issue. The court’s endorsement of Ship’s Equipment confirms that amendment applications should not routinely become mini-trials on validity. This procedural discipline protects the integrity of the main trial and ensures that expert evidence is properly assessed in the correct forum and at the correct time.
At the same time, the decision demonstrates that procedural restraint does not dilute the substantive statutory limits on amendments. Section 84(3) operates as a strict boundary: amendments that add matter or extend protection cannot be allowed, even if the amendment is motivated by a desire to overcome a patentability objection. For pharmaceutical patents—where claim format changes (including Swiss-style use claims) are often used to navigate patentability constraints—this case serves as a caution that format alone is not enough; the amendment must also comply with the “no additional matter/no extension” rule.
Finally, the discretionary factors discussed by the court are a reminder that timing and conduct matter. Where a patent is nearing expiry and the proprietor seeks amendments late in the day, courts may scrutinise whether the application is genuinely aimed at correcting permissible defects or is instead an attempt to secure an unfair advantage. Lawyers advising patent proprietors should therefore ensure that amendment strategies are pursued promptly, supported by full disclosure, and structured to satisfy both statutory requirements and equitable considerations.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including ss 25(5), 36, 38, 83(1), 84(3), and related provisions
- Medicines Act (Cap 176, 1985 Rev Ed), including s 12A(3)(a)
- Rules of Court (Singapore), including O 87A r 11(1)
- UK Patents Act 1977 (referenced for comparative context)
- CIPA Guide to the Patents Act (referenced for interpretive guidance)
Cases Cited
- Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2016] SGHC 106
- Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2017] SGCA 45
- Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781
- Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other and other suits [2005] 3 SLR(R) 389
- Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561
- Texas Instruments Ltd v Hyundai Electronics UK Ltd (1999) 22(12) IPD 22116 (Ch D (Patents Ct))
- Richardson-Vicks Inc’s Patent [1995] RPC 568
Source Documents
This article analyses [2016] SGHC 106 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.